|
Philadelphia-based Blues
affiliate Independence Blue Cross on Jan. 26 said it will launch an Advanced Network for Gene-Based
Therapeutics in March of this year. The insurer is partnering with Penn
Medicine and Children’s Hospital of Philadelphia in the creation of the new
network, noting both providers “have played pivotal roles in the development
and clinical trials of first-in-the-nation gene-based therapies.” While the
network is intended to help Independence members access gene therapies, the
press release noted that Luxturna and Zynteglo, both covered under
Independence’s medical benefit, will “continue to require precertification.”
Independence is currently the second-largest insurer in Pennsylvania, with 1,993,695
members. |
No comments:
Post a Comment